1[1]Timsina MP, Martin GP, Marriott C, et al. Drug delivery to the respiratory tract using dry powder inhalers[J]. Int J Pharm, 1994, 101 (1): 1 - 13.
2[2]Komada F, Iwakawa S, Yamamoto N, et al. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung[J]. J Pharm Sci, 1994, 83(6): 863 - 867.
3[3]Steckel H, Müller BW. In vitro evaluation of dry powder inhalers. Ⅰ. Drug deposition of commonly used devices [J]. IntJPharm, 1997, 154(1):19-29.
6[6]Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler[J]. Int J Pharm, 1994, 102(2): 127 - 132.
7[7]Davies PJ, Hanlon GW, Molyneux AJ. An investigation into the deposition of inhalation aerosol particles as a function of airflow rate in a modified ‘kirk lung'[J]. J Pharm Pharmacol, 1976, 28(12) :908- 911.
8[8]Hickey AJ, Concessio NM. Descriptors of irregular particle morphology and powder properties[J]. Adv Drug Deliv Rev,1997, 26(1):29-40.
9[9]Zeng XM, Pandhal KH, Martin GP. The influences of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols[J].Int J Pharm, 2000, 197(1/2) :41 - 52.
10[10]Bennett FS, Carter PA, Rowley G, et al. Modificaton of electrostatic charge on inhaled carrier lactose particles by addition of fine particles[J]. Drug Dev Ind Pharm, 1999,25(1):99- 103.
